CD8A and melanoma: Hewitt et al. designed an intratumoral IL-12 mRNA therapy strategy that linked the mRNA sequence of mIL-12 and MED11191 to generate a linked monomeric IL-12p70 (IL-12B-IL-12A), a single intratumoral dose of which effectively induced IFN-γ and CD8+ T cell-dependent tumor regression in a mouse model with melanoma as well as reducing undesirable toxicity [41].